Mindfulness-based treatments for co-occurring depression and substance use disorders: what can we learn from the brain?
- PMID: 20331548
- PMCID: PMC2905496
- DOI: 10.1111/j.1360-0443.2009.02890.x
Mindfulness-based treatments for co-occurring depression and substance use disorders: what can we learn from the brain?
Abstract
Both depression and substance use disorders represent major global public health concerns and are often co-occurring. Although there are ongoing discoveries regarding the pathophysiology and treatment of each condition, common mechanisms and effective treatments for co-occurring depression and substance abuse remain elusive. Mindfulness training has been shown recently to benefit both depression and substance use disorders, suggesting that this approach may target common behavioral and neurobiological processes. However, it remains unclear whether these pathways constitute specific shared neurobiological mechanisms or more extensive components universal to the broader human experience of psychological distress or suffering.We offer a theoretical, clinical and neurobiological perspective of the overlaps between these disorders, highlight common neural pathways that play a role in depression and substance use disorders and discuss how these commonalities may frame our conceptualization and treatment of co-occurring disorders. Finally, we discuss how advances in our understanding of potential mechanisms of mindfulness training may offer not only unique effects on depression and substance use, but also offer promise for treatment of co-occurring disorders.
Conflict of interest statement
Comment in
-
Commentaries on Brewer et al. (2010): Mindfulness-specific or generic mechanisms of action.Addiction. 2010 Oct;105(10):1707-8; discussion 1709-10. doi: 10.1111/j.1360-0443.2010.03013.x. Addiction. 2010. PMID: 20860074 No abstract available.
-
Commentaries on Brewer et al. (2010): Mindfulness-specific or generic mechanisms of action.Addiction. 2010 Oct;105(10):1708-9; discussion 1709-10. doi: 10.1111/j.1360-0443.2010.03044.x. Addiction. 2010. PMID: 20860075 No abstract available.
References
-
- COSIGClinical Protocol Committee. Definition of the Co-occurring Disorders Population (SAMHSA) 2006
-
- Kilgus M, Maxmen JS, Ward NG. Essential Psychopathology and Its Treatment. New York: Norton; 2009.
-
- Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transitions: 2002–2030. Ann Trop Med Parasitol. 2006;100:481–99. - PubMed
-
- Davis LL, Rush JA, Wisniewski SR, et al. Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohort. Comprehensive Psychiatry. 2005;46:81. - PubMed
-
- Davis L, Uezato A, Newell JM, Frazier E. Major depression and comorbid substance use disorders. Current Opinion in Psychiatry. 2008;21:14–18. - PubMed
Publication types
MeSH terms
Grants and funding
- T32-DA007238/DA/NIDA NIH HHS/United States
- K12-DA00167/DA/NIDA NIH HHS/United States
- RL1 AA017539/AA/NIAAA NIH HHS/United States
- T32 AA007455/AA/NIAAA NIH HHS/United States
- P50 DA009241/DA/NIDA NIH HHS/United States
- T32 DA007238/DA/NIDA NIH HHS/United States
- K12 DA000167/DA/NIDA NIH HHS/United States
- R01 DA020908/DA/NIDA NIH HHS/United States
- R25 MH071584/MH/NIMH NIH HHS/United States
- P50 DA09241/DA/NIDA NIH HHS/United States
- K24 DA017899/DA/NIDA NIH HHS/United States
- T32 AA 07455-24/AA/NIAAA NIH HHS/United States
- T32 MH019961/MH/NIMH NIH HHS/United States